Breanna O'Reilly

Analyst @ RA Capital Management

[No Patient Left Behind @NPLB_org]

The FDA will have a new leader at a pivotal moment for US biomedical innovation. We’re joining a coalition of leaders to support Dr. Richard Pazdur for the role.

FDA needs a leader with scientific credibility, consistency + proven leadership.

Sign: https://t.co/x2TLx6CvHB

[Peter Kolchinsky @PeterKolchinsky]

We analyzed impact of CMS's "experimental" GLOBE/GUARD policies to cap US prices at what other countries pay (answer: backfire). Note: doesn't lower what patients pay... that's a function what insurance gets away with charging sick people out of pocket. https://t.co/tdV9MOpvDN

[No Patient Left Behind @NPLB_org]

3.8 million Americans are living with breast cancer.
1 in 8 women will be diagnosed.

#Biotech startups are developing treatments, and if you pay insurance or invest, you may be helping.

🔗 https://t.co/pigLD3JS69

#CommunityQuest #BreastCancer #FixInsurance #ProtectInnovation

[Breanna O'Reilly @boreilly01]

No one fakes cancer to get free chemo. Let's fix insurance. Please visit https://t.co/MTD04ZUXP0 to learn more.

[No Patient Left Behind @NPLB_org]

You should never have to fight cancer AND your insurance company.

Half of cancer patients abandon treatment when out-of-pocket costs exceed $2,000.

Prescribed medicines, “covered” by an insurer, should be affordable with low or no out-of-pocket cost.

Let’s #FixInsurance

[No Patient Left Behind @NPLB_org]

If you have Type 1 diabetes, insulin keeps you alive. Why do health plans make you “prove” you need it by charging a copay on top of premiums? No Patient Left Behind is working to #FixInsurance & cap high out-of-pocket costs for prescribed medicines. #T1D #diabetes

[No Patient Left Behind @NPLB_org]

It's just not right... why does insurance charge people out-of-pocket for a medicine no one would take if they didn't have to?

We need to cap these costs for patients and #fixinsurance.

Please share and help, @MariahCarey , @jessicaalba, @Eminem, @Pink, @JeromeBettis36!

[Peter Kolchinsky @PeterKolchinsky]

What no one has yet recognized about Biosecurity is that Americans won't care about who invents or doesn't invent new medicines if they don't think they will be able to afford them anyways.

https://t.co/C382oNGHAj

We need pro-AFFORDABLE innovation policy, not just pro-innovation policy, which means capping what insurance can patients in charge out of pocket costs. What's the point of charging a copay for chemo? Who over-utilizes that? Like if the copay were zero, what reasonable thinks people will fake cancer to joyride chemo?

Unfortunately, many Democrats are still pushing price controls. With the election approaching, listen to how they will keep pounding on the idea pricing all drugs 9 years after launch... or 5 years... or right off the bat. Sure, maybe they want to protect the US biomedical innovation ecosystem from China, but only so that they can undermine it themselves with price controls and show voters ("I did that!"). These politicians will cynically sell out Americans' biomedical future for their votes today.

A small, smart group of Democrats and many Republicans understand that innovation is driven by patent-lengths of market-based rewards, not government price controls. They are wisely proposing a 9-13 fix to the IRA to make sure that all drugs get up to 13 years of their patent life (which averages 14 year normally) after launch. That fix is essential to restore incentives for small molecules of diseases of aging and align with the pro-US-innovation intent of the Biosecurity Act.

@IAmBiotech @PhRMA @NPLB_org

[Dr. Allyson Sgro @AllysonSgro]

Preprint approved! Check out our latest by @Huhu_Chuqiao @xinwinner and collaborators: https://t.co/8ZvrB9dm4r

[Sam @SamGhilardi]

1/ 8 Our lab's first preprint and my first paper thread, wherein we chase an unexpected microscopy observation and get to do some modeling (with @bio_MARK_er )and TEM imaging along the way. https://t.co/8m2hgfiRWE

It starts with this image of dermal myofibroblasts:

[Mark Aronson @bio_MARK_er]

Great lab mates make going to lab in the middle of a blizzard AND a pandemic always a good time, couldn't imagine doing this with anyone else #PhDedicated #SGROnanigans

[Breanna O'Reilly @boreilly01]

Congrats to @dpmcintyre7
This is an incredible accomplishment!

[David McIntyre @dpmcintyre7]

Beyond excited to be able to talk about my summer helping build @BU_Tweets COVID-19 testing facility from scratch. The facility can process up to 6,000 samples per day and recently ran its 200,000th test.

[Daniel J. Cohen (CohenLab at Princeton) @DJCohenEtAl]

First lab paper is out! We're herding cells with programmable electric fields using a device called SCHEEPDOG! We significantly updated the original biorXiv with some exciting new analyses. Special shoutouts to @tomzajdel and @GawoonS! https://t.co/2fgso9vgcL

[Dr. Allyson Sgro @AllysonSgro]

Tomorrow, my lab and I will be organizing a chat about how we as individuals can work to demolish anti-Black racism in academia. We'll be meeting on the BU COM Lawn at 2 PM before heading out to the #ShutDownSTEM #BlackLivesMatter march at 2:45 PM. Please DM for Zoom details.

[Breanna O'Reilly @boreilly01]

Do you ever find yourself wondering how your cells miraculously work together to repair damaged tissues? @SamGhilardi, @AllysonSgro and I do!!! And we wrote all about it. Check out our new review on how intracellular signaling coordinates tissue repair! https://t.co/cjGwysULZC

[Dr. Allyson Sgro @AllysonSgro]

Took the lab out for axe throwing to close out the year. Some anonymous lab members will clearly hold their own when the apocalypse comes. #SGROnanigans

[Centre for Genomic Regulation (CRG) @CRGenomica]

📚 New paper out! Researchers at #CRG develop a new methodology that makes it possible to study the mechanical properties of cells and tissues in vivo. The study, published in @CurrentBiology, sheds some light on embryogenesis.

[Breanna O'Reilly @boreilly01]

So excited to meet all of our wonderful mentors tonight! It’s been so fun taking this idea to reality.

[Joanna Y. Lee, Ph.D. @Joanna_Y_Lee]

Our first bioRxiv pre-print! YAP is essential for mechanotranduction in 2D culture, but there was no YAP activation in 3D culture or cancer patient samples. Turns out, patient samples have 10x smaller nuclei than cells in 2D, required for YAP activation. @StanfordEng @StanfordMed

[Eugene Katrukha 🇺🇦 @katpyxa]

A visual explanation of image histogram from @anvaka (https://t.co/5QoF0JZWSh), very helpful tool for image analysis teaching